$KERX recovery $7.25 Nasdaq GM 6-bagger correcte
Post# of 39
Posted On: 07/10/2016 1:50:08 PM
$KERX recovery $7.25
Nasdaq GM
6-bagger corrected.
called 2/26/12 by hyrpowr $3.00
Website
Shares Outstanding: 105.82M
Float: 71.17M
% Held by Insiders: 26.59%
% Held by Institutions: 61.50%
Shares Short (as of Jun 15, 2016): 19.88M
Short Ratio (as of Jun 15, 2016): 15.12
Short % of Float (as of Jun 15, 2016): 25.46%
Shares Short (prior month): 19.65M
Headlines
Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on providing therapies for patients with renal disease in the United States. Its lead product Auryxia (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes, as well as treats iron deficiency anemia. Auryxia is also used to control serum phosphorus levels in patients with chronic kidney disease on dialysis. The company has licensing and collaboration agreements with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of Auryxia in Japan. It also has strategic alliance with Panion & BF Biotech, Inc. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in Boston,
Nasdaq GM
6-bagger corrected.
called 2/26/12 by hyrpowr $3.00
Website
Shares Outstanding: 105.82M
Float: 71.17M
% Held by Insiders: 26.59%
% Held by Institutions: 61.50%
Shares Short (as of Jun 15, 2016): 19.88M
Short Ratio (as of Jun 15, 2016): 15.12
Short % of Float (as of Jun 15, 2016): 25.46%
Shares Short (prior month): 19.65M
Headlines
Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on providing therapies for patients with renal disease in the United States. Its lead product Auryxia (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes, as well as treats iron deficiency anemia. Auryxia is also used to control serum phosphorus levels in patients with chronic kidney disease on dialysis. The company has licensing and collaboration agreements with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of Auryxia in Japan. It also has strategic alliance with Panion & BF Biotech, Inc. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in Boston,
(0)
(0)